Abstract
Cancer-associated inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers. The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin. Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug. The prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the side effects of cisplatin. Platin-A exhibits anticancer and anti-inflammatory properties which are better than those for the combined use of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered as a single prodrug.
Original language | English (US) |
---|---|
Pages (from-to) | 1963-1967 |
Number of pages | 5 |
Journal | Angewandte Chemie - International Edition |
Volume | 53 |
Issue number | 7 |
DOIs | |
State | Published - Feb 10 2014 |
Externally published | Yes |
Keywords
- antitumor agents
- drug design
- inflammation
- platinum
- prodrugs
ASJC Scopus subject areas
- Catalysis
- Chemistry(all)